Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of preimplantation genetic testing in sickle cell disease: insights from a single-center experience.

Journal of assisted reproduction and genetics·2026
Same author

Evaluating the Impact of Patient Education on Knowledge, Self-Efficacy, and Quality of Life in Chronic Obstructive Pulmonary Disease.

La Clinica terapeutica·2025
Same author

The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.

Oral oncology·2024
Same author

Position paper on advancing sickle cell disease management in France by bridging the clinical practices and guidelines through expert insights.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2024
Same author

Randomized preclinical study of machine perfusion in vascularized composite allografts.

The British journal of surgery·2021
Same author

Improved survival prediction for oropharyngeal cancer beyond TNMv8.

Oral oncology·2021

Related Experiment Video

Updated: Jun 30, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Epidermal growth factor receptor-targeted therapy.

C M West1, L Joseph, S Bhana

  • 1Academic Radiation Oncology, The University of Manchester, Christie Hospital, Manchester M20 4BX, UK. catharine.west@manchester.ac.uk

The British Journal of Radiology
|October 10, 2008
PubMed
Summary

High epidermal growth factor receptor (EGFR) expression in tumors worsens radiotherapy outcomes. Combining anti-EGFR therapies with radiation shows promise for cancer treatment, with research focusing on optimal scheduling and biomarkers.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Experiment Videos

Last Updated: Jun 30, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Area of Science:

  • Oncology
  • Radiation Oncology
  • Molecular Biology

Background:

  • High epidermal growth factor receptor (EGFR) expression is a common feature in human tumors.
  • Elevated EGFR expression is linked to poorer outcomes in radiotherapy.
  • Specific cancer types, like head and neck squamous cell carcinoma, show benefit from accelerated radiotherapy when EGFR is highly expressed.

Purpose of the Study:

  • To explore the potential of combined modality therapies involving radiation and epidermal growth factor receptor (EGFR) antagonists for curative cancer treatment.
  • To investigate the mechanisms by which anti-EGFR strategies potentiate radiotherapy effects.
  • To identify key issues for designing future clinical trials, including optimal scheduling and biomarker development.

Main Methods:

  • Review of existing research on EGFR expression in tumors and its prognostic value.
  • Analysis of mechanisms through which anti-EGFR agents interact with radiotherapy.
  • Discussion of clinical trial design considerations for combined therapies.

Main Results:

  • Anti-EGFR strategies enhance radiotherapy efficacy through various mechanisms, including the inhibition of deoxyribonucleic acid repair.
  • Other contributing mechanisms include effects on angiogenesis, cellular differentiation, and the immune response.
  • Combined radiation and EGFR antagonist therapy is of significant interest for cancer treatment.

Conclusions:

  • Combined modality therapies of radiation and EGFR antagonists offer a promising avenue for curative cancer treatment.
  • Future research should focus on optimizing treatment schedules and developing biomarkers for patient selection.
  • Understanding the interplay between EGFR, radiotherapy, and DNA repair is crucial for advancing cancer therapy.